Michael Foley

Broad Institute — United States

Medicine · Health Sciences

48h-index7.9kcitations130works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Malaria Research and Control(51), Monoclonal and Polyclonal Antibodies Research(29), Mosquito-borne diseases and control(24), Complement system in diseases(13), Glycosylation and Glycoproteins Research(12)

Publications130 total

Author Correction: Diversity-oriented synthesis yields novel multistage antimalarial inhibitors
Nature·2025Open Access
Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis
mAbs·2025· 2 citedOpen Access
Second Generation I-Body AD-214 Attenuates Unilateral Ureteral Obstruction (UUO)-Induced Kidney Fibrosis Through Inhibiting Leukocyte Infiltration and Macrophage Migration
International Journal of Molecular Sciences·2024· 1 citedOpen Access
AD-214 anti CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis
2024Open Access
A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
Nature Communications·2024· 12 citedOpen Access
A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
2023· 1 citedOpen Access
ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption
Journal of Biological Chemistry·2023· 8 citedOpen Access
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4
JCI Insight·2022· 17 citedOpen Access
CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis
Respiratory Research·2020· 59 citedOpen Access
Emerging Role of CXCR4 in Fibrosis
2020· 1 cited
The challenges of complex molecular testing pathways and the benefits of in-house testing
Lung Cancer·2020
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
mAbs·2019· 28 citedOpen Access
Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain
mSphere·2019· 27 citedOpen Access
Retraction Note: Selective killing of cancer cells by a small molecule targeting the stress response to ROS
Nature·2018· 11 citedOpen Access
Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
Scientific Reports·2018· 77 citedOpen Access
Inhibition of the chemokine receptor CXCR4 reduces pathology in a laser induced mouse model of choroidal neovascularization
Investigative Ophthalmology & Visual Science·2017Open Access
The difference theology makes: a reflection on the first margin note in Thomas More's <i>Utopia</i>
Moreana·2017· 1 cited
Shark-Derived Single Domain Antibodies Targeting Apolipoprotein E
Biophysical Journal·2017Open Access
i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4
Journal of Biological Chemistry·2016· 65 citedOpen Access
Correction: Corrigendum: Selective killing of cancer cells by a small molecule targeting the stress response to ROS
Nature·2015· 29 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Leann Tilley(19), Robin F. Anders(17), Andrew M. Coley(11), Joanne L. Casey(9), Raymond S. Norton(7), Alan F. Cowman(6), Vincent J. Murphy(4), Adrian H. Batchelor(4), Olan Dolezal(4), Stewart D. Nuttall(4), Anthony N. Hodder(4), P.M. Loria(3), Christopher A. MacRaild(3), Kathy Parisi(3), Rosella Masciantonio(3), Karen S. Harris(3), James G. Beeson(3), Christopher G. Adda(3), Katherine Griffiths(3), Alykhan F. Shamji(2)